Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC)

Jazmine Arévalo¹, David Lorente², Enrique Trilla¹, María Teresa Salcedo³, Juan Morote² & Anna Meseguer¹,4*

Clear cell renal cell carcinoma (ccRCC) is the most prevalent and aggressive histological subtype of renal carcinoma. To date, ccRCC is considered the most lethal urological cancer due to its asymptomatic phenotype together with its resistance to chemotherapy and radiotherapy. If ccRCC is detected in early stages, partial or radical nephrectomy is the first-line treatment and can prolong survival in 65% of patients. However, 30% of initial organ-confined tumors treated by surgical resection develop local recurrence or metastasis during the follow-up. Conversely, if detection occurs in advanced metastatic stage, there are very limited and no completely effective treatments to date. Furthermore, adjuvant therapy has only been approved for metastatic patients, yet less than 50% of cases respond to treatment likely because of the underlying molecular heterogeneity among tumors.

At present, prognosis after surgery has been modestly successful. Classic clinicopathologic features such as Fuhrman grade and tumor-node-metastasis (TNM) stage are the usual predictors of clinical outcome, and despite they provide significant information, they are not accurate enough to predict disease progression by themselves. So far, although numerous and extensive studies on the genetic and biochemical features of ccRCC have been performed, there are few usable markers only related to treatment outcome. This scenario poses the urgent need to identify specific biomarkers that can be used for early diagnosis, prognosis and to develop treatment strategies for all ccRCC patients.
In this context, previous studies from our group brought to light the role of the signal transducer and activator of transcription 3 (STAT3) in ccRCC by demonstrating that its activation resulted from the overexpression of the human hepatitis A virus cellular receptor 1 (hHAVCR1), also known as kidney injury molecule 1 (KIM1)\(^\text{12}\). STAT3 is a ubiquitous transcription factor that regulates the expression of hundreds of genes involved in essential biological processes, thus, it is not surprising that its aberrant activation has been related to the onset of more than 50% of all human cancers\(^\text{13}\). Classically, STAT3 activation relies on the phosphorylation of its tyrosine 705 (Y705)\(^\text{14}\), nonetheless, recent reports described the phosphorylation of its serine 727 (S727) as a novel and non-canonical mechanism of STAT3 activation\(^\text{15,16}\). Previously, and in order to establish the role of STAT3 in the ccRCC, our group analyzed the expression of both phosphorylated residues (pY705 and pS727) on localized tumor samples from 98 ccRCC patients who had not undergone chemo- or immunotherapy before or after nephrectomy. Results from that study showed that only nuclear pS727-STAT3 -non pY705- levels were associated with the clinical outcome of ccRCC patients, therefore, it was proposed as an independent factor of overall survival\(^\text{12}\).

In the present study, we evaluated the prognostic value of pS727-STAT3 on a tissue microarray (TMA) from a new cohort of 82 ccRCC patients followed-up for 10 years, and we correlated its expression levels, both in the nucleus and in the cytosol, with the clinical outcome of ccRCC patients. Moreover, the major difference from our previous patients’ cohort\(^\text{12}\) was the inclusion of individuals who underwent tyrosine kinase inhibitors (TKIs) treatment after nephrectomy. These patients allowed the evaluation of the pS727-STAT3 potential to discriminate between those with different responses to adjuvant therapy.

Results

Study group. The present study included 56 men (68.3%) and 26 women (31.7%), median age: 72 years range: 38–92, with ccRCC. The tumor was on the right side in 43 cases (52.4%) and on the left side in 39 cases (47.6%). A total of 77 patients (93.9%) presented with localized tumors and 5 (6.1%) with metastasis. Sixty-eight patients (82.9%) underwent radical nephrectomy, while 14 (17.1%) underwent nephron-sparing surgery (tumorectomy or partial nephrectomy). Fuhrman grade grouped I–II consisted of 42 cases (51.2%), and III–IV consisted of 40 cases (48.8%). The most frequently observed tumor size (pT) stages were pT1a in 45.1% and pT1b in 23.2%. Lymphovascular invasion was present in only 3.6% of patients, while the risk group was low in 43.9%, intermediate in 34.1%, and high in 22% of patients studied. Finally, 15 patients (18.3%) who recidivated after surgery, underwent tyrosine kinase inhibitors (TKIs) treatment (Table 1). All patients were considered for statistical analysis. Univariate analysis for cancer-specific survival following kidney surgery was statistically significant for the Fuhrman grade (I–II vs III–IV, \(p = 0.002\)); risk group (low vs high, \(p = 0.006\)); and tumor size (1–2 NO M0 vs 3–4 N1,2 M1, \(p = 0.001\)) (Table 2).

ccRCC tumors exhibit different pS727-STAT3 location patterns between the nucleus and the cytosol.

Immunohistochemical analyses showed that unaffected adjacent tissue was negative for pS727-STAT3 staining (Fig. 1, left panel), whereas ccRCC tumors exhibited positive staining both in the nucleus and the cytosol (Fig. 1, right panel). The threshold to distinguish patients with high or low pS727-STAT3 expression was determined as the median value based on the percentage and intensity of stained cells (H-score), thus, cutoff values were set at 80 and 40 (nucleus and cytosol, respectively). According to the H-score, 44 tumors (53.6%) exhibited strong nuclear staining whilst 41 tumors (50%) showed intense cytosolic staining. Conventionally, an activated STAT3, either by Y705 or S727 phosphorylation, is predominantly located within the nucleus regulating gene expression; however, recent studies have demonstrated that STAT3 phosphorylated at its S727 also exerts non-genomic functions in the mitochondria and the endoplasmic reticulum (ER)\(^\text{15}\). These latest findings might explain the presence of pS727-STAT3 in both compartments observed in our study. More interestingly, different expression patterns were also observed among ccRCC tumors where pS727-STAT3 was i) only present in the nucleus (Fig. 1a), ii) completely cytosolic (Fig. 1b), or iii) simultaneously detected in both cellular compartments (Fig. 1c) but without a significant correlation between their independent H-scores (\(p = 0.2\)). The frequency of these expression patterns is summarized in Table 3. These results suggest that different pS727-STAT3 location patterns could determine different STAT3 functions during ccRCC development and progression.

High nuclear and cytosolic pS727-STAT3 levels identify patients with the lowest overall survival among those with advanced-stage ccRCC disease.

Upon signal intensity evaluation using the H-score, levels of pS727-STAT3 were correlated to the clinical outcome of ccRCC patients. Kaplan–Meier estimates of mortality (120 months overall survival) showed statistically significant differences in overall survival rates between patients in the same advanced-stage clinicopathologic group with high versus low pS727-STAT3 H-score: Fuhrman grade III–IV (nuclear \(p = 0.005\), cytosolic \(p = 0.027\)), high-risk group (nuclear \(p = 0.018\), cytosolic \(p = 0.005\)), and tumor size pT3-4 N1,2 M1 (nuclear \(p = 0.009\), cytosolic \(p = 0.012\)) (Fig. 2a,b). Moreover, multivariate analysis for nuclear (\(p = 0.002\); 95% CI 1.004–1.026) and cytosolic (\(p = 0.040\); 95% CI 1.003–1.042) pS727-STAT3 H-score indicates that its presence—regardless of its location—significantly correlates with patient survival though cytosolic levels were not statistically as relevant as those in the nucleus (Table 4). Overall, these results demonstrate that high pS727-STAT3 levels—either in the nucleus or in the cytosol—represent a prognostic factor of low overall survival in advanced-stage ccRCC patients independently of the clinicopathological parameters.

ccRCC patients with high nuclear expression of pS727-STAT3 exhibit increased disease-free survival after adjuvant treatment.

In the present study, patients who received adjuvant treatment \((n = 15)\) in response to recurrence after surgery were found included in the high nuclear pS727-STAT3 levels...
### Table 1. Patients and tumor characteristics. *Neph. sparing* nephron-sparing surgery, *pT* tumor size, *pN* nodal involvement, *pM* metastasis.

| Variable                              | No. (%) or variable unit |
|---------------------------------------|--------------------------|
| Patient age (years)                   |                          |
| Median                                | 72.17                    |
| Mean (range)                          | 70.56 (38–92)            |
| Sex, No. (%)                          |                          |
| Male                                  | 56 (68.3)                |
| Female                                | 26 (31.7)                |
| Tumor side                            |                          |
| Right                                 | 43 (52.4)                |
| Left                                  | 39 (47.6)                |
| Clinical presentation, No. (%)        |                          |
| Radical                               | 68 (82.9)                |
| Neph. sparing                         | 14 (17.1)                |
| Adjuvant treatment, No. (%)           | 15 (18.3)                |
| Fuhrman grade, No. (%)                |                          |
| I–II                                  | 42 (51.2)                |
| III–IV                                | 40 (48.8)                |
| Primary tumor size, No. (%)           |                          |
| *pT1a*                                | 37 (45.1)                |
| *pT1b*                                | 19 (23.2)                |
| *pT2*                                 | 4 (4.9)                  |
| *pT3a*                                | 13 (15.9)                |
| *pT3b*                                | 8 (9.8)                  |
| *pT4*                                 | 1 (1.2)                  |
| Lymphovascular invasion, No. (%)      |                          |
| *pNx*                                 | 20 (24.4)                |
| *pN0*                                 | 59 (72.0)                |
| *pN1*                                 | 2 (2.4)                  |
| *pN2*                                 | 1 (1.2)                  |
| Metastasis, No. (%)                   |                          |
| *pM0*                                 | 77 (93.9)                |
| *pM1*                                 | 5 (6.1)                  |
| Risk group, No. (%)                   |                          |
| Low                                   | 36 (43.9)                |
| Intermediate                          | 28 (34.1)                |
| High                                  | 18 (22.0)                |
| Follow-up (months)                    |                          |
| Median for all patients               | 79.57                    |
| Mean for all patients                 | 72.15 (2–112)            |

### Table 2. Cancer-specific survival following renal surgery.

| Variable (grouped) | Univariate analysis mean (95% CI) | p value |
|--------------------|-----------------------------------|---------|
| Fuhrman grade      |                                   |         |
| I–II versus        | 105.9 (102.5–109.2)               |         |
| III–IV             | 88.3 (77.6–99.0)                  | 0.002   |
| Risk group         |                                   |         |
| Low versus         | 101.0 (94.5–107.4)                |         |
| High               | 91.7 (80.8–102.5)                 | 0.006   |
| Primary tumor size (pT) |                              |         |
| 1–2 N0 M0 versus   | 105.0 (101.2–108.8)               | 0.001   |
| 3–4 N1,2 M1        | 79.0 (63.6–94.5)                  |         |
group (H-score ≤ 80) and advanced stages of the disease according to Fuhrman grade III-IV and tumor size pT3-4, N1,2 M1. Interestingly, the inclusion of these patients in our regression model resulted in a crossover of Kaplan–Meier curves, as observed at the top of the corresponding graphs (Fig. 2a). This particular observation indicates that these patients improved disease-free survival (~ 20 months) after TKIs treatment, and suggests that pS727-STAT3 detection could also be used as a prognostic biomarker for the stratification of patients by

**Figure 1.** pS727-STAT3 location patterns in ccRCC tumors. Representative images of pS727-STAT3 immunohistochemical analysis showing normal counterparts (left panel) completely negative and tumor samples (right panel) exhibiting positive staining arranged in different location patterns: (a) only nuclear pS727-STAT3; (b) only cytosolic pS727-STAT3, and (c) nuclear and cytosolic pS727-STAT3. Original magnification × 200.

| pS727-STAT3 | H-score | n   |
|-------------|---------|-----|
| Only nuclear | ≥ 80    | 24 (29.2%) |
| Only cytosolic | ≥ 40   | 21 (25.6%)  |
| Nuclear and cytosolic | ≥ 80, ≥ 40 | 20 (24.3%) |

**Table 3.** Incidence of different pS727-STAT3 expression patterns in ccRCC tumors.
indicating which ones (those with high nuclear pS727-STAT3 levels) are susceptible to respond to adjuvant treatment and improve overall survival.

Discussion
Although multiple risk factors have been associated with the development of ccRCC\textsuperscript{17}, to date, the molecular mechanisms behind its etiology are not completely understood which leads to a lack of effective biomarkers clinically usable to predict disease progression or to select patients for particular therapies. So far, the most promising biomarkers for ccRCC are associated with treatment outcome, ranging from clinical parameters

![Figure 2. Correlation of pS727-STAT3 H-score with clinical outcome. Kaplan–Meier estimates of 120 months overall survival showing that patients with high pS727-STAT3 H-score (green lines) are prone to die earlier over time when compared to low pS727-STAT3 H-score patients (blue lines), especially those in advanced stages of the disease (Fuhrman grade III–IV, high risk, and tumor size pT3-4 N1,2 M1). Nuclear (blue line, HS < 80; green line, HS > 80) (left panel) and cytosolic (blue line, HS < 40; green line, HS > 40) (right panel) pS727-STAT3 H-score expression levels correlated to mean survival of ccRCC patients according to (a) Fuhrman grade (I–II, III–IV), (b) risk group (low, high), and (c) tumor size (pT1-2 N0 M0, pT3-4 N1,2 M1).](#)

| H-score | Mean survival (95% CI) (months) | p value |
|---------|--------------------------------|---------|
| Nuclear pS727-STAT3 | | |
| < 80 | 107.9 (103.7–112.0) | 0.002 |
| ≥ 80 | 88.4 (79.3–97.6) | |
| Cytosolic pS727-STAT3 | | |
| < 40 | 103.0 (95.4–110.7) | 0.040 |
| ≥ 40 | 92.9 (85.0–100.9) | |

Table 4. Overall survival of ccRCC patients considering the expression of pS727-STAT3.
and endogenous substances (such as blood pressure or plasma proteins) to pathobiological features specific to individual tumors (such as mutations)\(^\text{11-12}\). Therefore, the study of molecular markers associated with ccRCC development and progression becomes urgent to provide a better understanding of the molecular pathogenesis of the disease, and consequently, its clinical outcome. In that scenario, a previous study from our group pointed out the role of STAT3 in ccRCC by demonstrating, for the first time, that nuclear presence of its phosphorylated form (at S727) correlated with the overall survival of ccRCC patients\(^\text{12}\). Accordingly, over the past years, it has been extensively confirmed that abnormal activation of STAT3—either by Y705 or S727 phosphorylation—is a key event that contributes to oncogenesis in several tumors other than ccRCC\(^\text{13}\).

Here, we aimed to gain further insight into the value of pS727-STAT3 as a clinically relevant biomarker in ccRCC. Our results demonstrate that pS727-STAT3 levels constitute an independent prognostic factor of overall survival that divides advanced-stage ccRCC patients into two groups: those with low pS727-STAT3 levels and better prognosis, and those with high pS727-STAT3 levels prone to die earlier over time (Fig. 2a,b). Aligned with our results, other studies evaluating STAT3 activation (via pY705 or pS727) on tissue samples of other cancer types such as cervical intraepithelial neoplasia (CIN) and prostate cancer, have also reported a significant correlation of pS727-STAT3 levels to the clinical outcome of those patients\(^\text{18,19}\). These studies along with ours demonstrate that activation of STAT3 through S727 phosphorylation is indeed involved in the development of several malignancies, and suggest that pS727-STAT3 may be responsible for the expression of a subset of genes (different from those regulated by pY705) that promote a more aggressive tumoral phenotype.

Unlike our previous study, the present work included the analysis of cytosolic pS727-STAT3 levels due to recent findings indicating that STAT3 phosphorylation at S727 has an important role in the regulation of mitochondrial activity and modulation of Ca\(^{2+}\) release from the ER\(^\text{11}\), both processes in line with the pro-oncogenic role of STAT3. Several studies have demonstrated that mitochondrial STAT3 (mSTAT3), which refers to pS727-STAT3, contributes to the maintenance of energy balance and cell survival under specific cellular stress conditions such as Ras-mediated transformation\(^\text{20}\). Specifically, pS727-STAT3 in the mitochondria has been related to an optimal electron transport chain (ECT) activity, an increase in membrane polarization and ATP production, and enhancement of lactate dehydrogenase activity that, consequently, induces aerobic glycolysis and decreases reactive oxygen species (ROS) production\(^\text{11-20}\). In addition to these actions, protection from apoptosis is also triggered by inhibition of the mitochondrial permeability transition pore (MPTP) in collaboration with the ER\(^\text{21}\). In normal conditions, the regulation of Ca\(^{2+}\) homeostasis in the ER is mainly under the control of Ca\(^{2+}\) pumps and receptors activated by inositol 1,4,5-trisphosphate (IP\(_3\)) called IP\(_3\)R\(^\text{22}\). This process takes place at the mitochondria-associated membranes (MAMs), which locate at the interphase between the mitochondria and the ER\(^\text{23}\). As the membranes of both organelles are nearby, the excessive release of Ca\(^{2+}\) mediated by IP\(_3\)R, in particular IP\(_3\)R3, can lead to mitochondrial overload, which in turn triggers the opening of the MPTP and the initiation of the intrinsic apoptotic program\(^\text{27}\). Therefore, the ER-mitochondria space acts as a signaling hub for the activity of growth factors, oncogenes, and tumor suppressors that regulate IP\(_3\)R3 activity\(^\text{24}\). Since both pY705- and pS727-STAT3 localize to the ER and MAMs, phosphoablative mutants (Y705F and S727A) were used to evaluate their effect on IP\(_3\)R3-mediated Ca\(^{2+}\) release founding that only pSer727-STAT3 inhibited Ca\(^{2+}\) release by interacting with IP\(_3\)R3 and facilitating its degradation via the proteasome, thus, avoiding apoptosis\(^\text{26}\).

Our immunohistochemical analysis showed that ccRCC tumors exhibited three different location patterns of pS727-STAT3 between the nucleus and the cytosol. Specifically, pS727-STAT3 was found i) only in the nucleus, ii) only in the cytosol, or iii) in both compartments simultaneously; suggesting that pS727-STAT3 may exhibit different functions at certain stages of tumor development. It might be that pSer727-STAT3 controls transcription in the nucleus, while regulates energy metabolism in the mitochondria and apoptosis through the ER. Moreover, the presence of pS727-STAT3 in the cytosol, specifically in the mitochondria, might respond to a shift in cellular energy metabolism driving the initial stages of transformation in agreement with the Warburg effect\(^\text{28}\). Otherwise, the presence of pS727-STAT3 in the ER could represent a well-established anti-apoptotic mechanism in the late stages of tumor development. Nevertheless, to confirm this hypothesis, more experiments should be performed to determine whether a correlation between pS727-STAT3 expression pattern and the different stages of ccRCC development actually exists. In line with our data, analysis of pS727-STAT3 levels in CIN samples has also identified nuclear and cytosolic expression of pS727-STAT3, both correlating with nuclear expression of the cellular marker of proliferation Ki67\(^\text{18}\).

Besides the value of pS727-STAT3 as a prognostic factor of overall survival in ccRCC patients, our results also indicate that it may be as useful as a novel biomarker to select patients who are candidates for adjuvant therapy. In our cohort, patients who received anti-angiogenic treatment (TKIs) corresponded to those exhibiting metastases or lymphovascular invasion at the time of surgery. In turn, none of the patients with localized tumors received any adjuvant treatment because no information regarding possible benefits for them was available until now. A recent study reported that adjuvant sunitinib versus placebo significantly improved the median duration of disease-free survival in locoregional tumors of ccRCC patients at high risk for tumor recurrence after nephrectomy\(^\text{29}\). Based on this study and our observation that ccRCC patients with a high pS727-STAT3 expression—of which underwent TKIs treatment experienced a significant stabilization of the disease (~20 months), we postulated that determination of pS727-STAT3 levels at the time of surgery could indicate that patients with localized tumors might benefit from adjuvant treatment versus those that only will suffer the adverse effects. We reasoned that the incorporation of molecular markers such as pS727-STAT3 into conventional models (such as Fuhrman grade and TNM stage) might enhance their prognostic accuracy. In that regard, we rationalized that patients in advanced stages of the disease with low pS727-STAT3 expression levels might not need adjuvant treatment because they do not recidivate; however, those patients in the high pS727-STAT3 group could benefit from the treatment. Although the number of patients with adjuvant therapy included in our cohort (n = 15) narrows the interpretation of our results and a larger study is needed, we propose the pS727-STAT3 as a putative biomarker able to indicate treatment after surgery in all advanced-stage ccRCC patients.
In summary, the present study demonstrates that pS727-STAT3 expression, whether in the nucleus or the cytosol, correlates with a low overall specific cancer survival of ccRCC patients and represents an independent prognostic factor to classical clinicopathologic features. Moreover, we propose that measurement of pS727-STAT3 in tumor tissues at the time of surgery can determine which patients shall be treated with currently available adjuvant therapies to increase overall survival. Altogether, pS727-STAT3 represents a biomarker not only for the prognosis of the disease but also for the therapeutic stratification of ccRCC patients.

**Methods**

**Case selection.** Standard tumor data were obtained from 82 ccRCC patients treated with radical or partial nephrectomy between 2008 and 2010 and clinically followed up to 2017 at the Vall d’Hebron Hospital (Barcelona, Spain). Primary tumor histology was obtained from surgical resections and pathologic information was based on a re-review of all surgical samples to establish histologic subtype.

Clinical and pathologic information was retrospectively reviewed including date of diagnostic, demographics, tumor stage, Fuhrman grade, nodal and metastasis spread, initial and subsequent therapy, as well as outcome information. The anatomic extent of the tumors was classified using the TNM stage system, while prognostic stratification of ccRCC patients was scored using the University of California Los Angeles (UCLA) Integrated Staging System–Union Internationale Contre le Cancer (UICC) nomogram. Clinical and follow-up information was recorded by physician reports. Because of the availability of novel targeted therapies since 2008, patients who recidivated were treated with adjuvant therapy, nonetheless, all of them were included in the present study.

**Tissue microarray (TMA).** The TMA was constructed from paraffin-embedded samples of 82 ccRCC patients provided by the Department of Pathology at the Vall d’Hebron Hospital (Barcelona, Spain). One section from each specimen was stained with hematoxylin and eosin and reviewed for the selection of representative areas. For each sample, 3 representative areas of 1 mm diameter cores were obtained using a semi-automated tissue arrayer (Chemicon International). As controls, 3 cores of adjacent benign tissue far from the tumor were included. Finally, tissue cores were paraffin-embedded in a spaced array pattern 30.

Informed consent from all participants was obtained for the use of all human tissues in this study following the rules of the Spanish Biomedical Research Law. The ethics committee of the Hospital Universitari Vall d’Hebron (HUVH) approved the study protocol and the methodology was performed following the relevant guidelines and regulations.

**TMA immunohistochemistry.** Four-micrometer-thick sections from TMA blocks were cut using a microtome, deparaffinized overnight (ON) at 55°C, and hydrated into milli-Q H2O through sequential steps of graded ethanol. The immunohistochemistry (IHC) was performed using the EnVision + Dual Link System-HRP (DAB+) kit (Dako #K4065) according to the supplier’s instructions. Antigen retrieval was performed with sodium citrate buffer pH 6.0 (Dako #S2031) for 15 min. Endogenous peroxidase activity was quenched followed by unspecific binding blocking with 5% normal horse serum (Sigma Aldrich # H0146) for 1 h at room temperature (RT). For pS727-STAT3 staining, TMAs were incubated ON at 4°C with primary antibody α-pS727-STAT3 (Cell Signaling #9134) at a final dilution of 1:50. The secondary antibody (labeled polymer-HRP mouse/rabbit) was incubated for 1 h at RT. Finally, HRP detection with DAB-Chromogen and hematoxylin (Sigma Aldrich #HHS32) counterstaining were performed at RT for 20 min and 1 min, respectively. As a negative control, the primary antibody was incubated for 1 h at RT. For pS727-STAT3 staining, TMAs were incubated ON at 4°C with primary antibody α-pS727-STAT3 (Cell Signaling #9134) at a final dilution of 1:50. The secondary antibody (labeled polymer-HRP mouse/rabbit) was incubated for 1 h at RT. Finally, HRP detection with DAB-Chromogen and hematoxylin (Sigma Aldrich #HHS32) counterstaining were performed at RT for 20 min and 1 min, respectively. As a negative control, the primary antibody was incubated with non-immune bovine serum (Alpha Diagnostics # 20001-2-1).

**TMA evaluation.** pS727-STAT3 staining was scored by two renal pathology experts (MTS and ITR), blinded to clinicopathologic variables and fully independent to each other. pS727-STAT3 expression was evaluated in a semi-quantitative manner by immune-histo-score (H-score) based on the percentage and intensity of stained cells as follows: 0 = no appreciable staining; 1 = weak staining; 2 = moderate staining; and 3 = strong staining. Therefore, the H-score was calculated as 1 x (% weak) + 2 x (% moderate) + 3 x (% intense) ranging from 0 to 300 31. The inter-rater reliability between experts was substantial by having a Cohen's kappa of 0.75 for nuclear and 0.73 for cytosolic H-scores. For each ccRCC sample, 3 independent tissue cores were evaluated presenting an average coefficient of variance (CV) of 23.4%, therefore, H-score was expressed as the mean.

**Statistical analyses.** Correlations between pS727-STAT3 expression and clinicopathologic parameters were evaluated with the nonparametric Mann–Whitney U test. Kaplan–Meier survival curves were compared using the log-rank test and multivariate analysis was carried out using a Cox regression model to estimate the independent prognostic importance of clinicopathologic parameters. Concordance between experts’ scoring was determined using Cohen’s kappa statistic 32. Correlation between nuclear and cytosolic H-scores was defined using linear regression, while the correlation between replicates was assessed by calculating the coefficient of variance among samples. All the statistical analysis was performed with the Statistical Package for Social Sciences software (SPSS, IBM).

**Data availability**

The datasets analyzed during the current study are not publicly available due to privacy policies. Data are however available from the corresponding author on reasonable request and with permission of the Spanish Biomedical Research Law and the ethics committee of the Hospital Universitari Vall d’Hebron (HUVH).
References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7–30 (2018).
2. Cohen, H. T. & McGovern, P. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
3. Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet (London, England) 373, 1119–1132 (2009).
4. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913–924 (2015).
5. Uchida, K. et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int. J. Urol. 9, 19–23 (2002).
6. Levy, D. A., Slaton, J. W., Swanson, D. A. & Dinney, C. P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163–1167 (1998).
7. Gong, J., Maia, M. C., Dizman, N., Govindarajan, A. & Pal, S. K. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J. Urol. 3, 286–292 (2016).
8. De Mulder, P. H. M. Targeted therapy in metastatic renal cell carcinoma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 18(Suppl 9), ix98–ix102 (2007).
9. Zigeuner, R. et al. External validation of the mayo clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur. Urol. 57, 102–111 (2010).
10. Ficarra, V. et al. The ‘Stage, Size, Grade and Necrosis’ score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 103, 165–170 (2009).
11. Hsieh, J. J. et al. Targeted therapy in metastatic renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 1–19 (2017).
12. Cuadros, T. et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in ccRCC and determines tumor progression and patient outcome. Cancer Res. 74(5), 1416–1428 (2014).
13. Guanzo, A. C., Fernandez, C. D., Garama, D. J. & Daniel, J. STAT3: A multifaceted oncoprotein. Growth Factors 36, 1–14 (2018).
14. Schindler, C., Levy, D. E. & Decker, T. JAK-STAT signaling: From interferons to cytokines. J. Biol. Chem. 282, 20059–20063 (2007).
15. Aznar, S. et al. Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in RhoA GTPase oncogenic transformation. Mol. Biol. Cell 12, 3282–3294 (2001).
16. Avalle, L. & Poli, V. Nucleus, mitochondrion, or reticulum? STAT3 à La Carte.
17. Karami, S.
18. Yang, S. F.
19. Tammineni, P.
20. Gough, D. J.
21. McHugh, M. L.
22. Wegrzyn, J.
23. Zhang, Q.
24. Boengler, K., Hilfiker-Kleiner, D., Heusch, G. & Schulz, R. Inhibition of permeability transition pore opening by mitochondrial 
25. Mak, D. O. D. & Foskett, J. K. Inositol 1,4,5-trisphosphate receptors in the endoplasmic reticulum: A single-channel point of view.
26. Warburg, O. On the origin of cancer cells. Science (80-) 123, 309–314 (1956).
27. Motzer, R. J. et al. Adjuvant Sunitinib for high-risk renal cell carcinoma after nephrectomy: Subgroup analyses and updated overall survival results. Eur. Urol. 73, 62–68 (2018).
28. Skacel, M., Skilton, B., Pettry, J. D. & Tubbs, R. R. Tissue microarrays: A powerful tool for high-throughput analysis of clinical specimens: A review of the method with validation data. Appl. Immunohistochem. Mol. Morphol. AJMM 10, 1–6 (2002).
29. Detre, S., Saciani Jotti, G. & Dowsett, M. A ‘quickscore’ method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876–878 (1995).
30. McHugh, M. L. Interrater reliability: The kappa statistic. Biochem. Medica 22, 276–282 (2012).

Acknowledgements

We would like to thank Dr. Cantero-Recasens for his helpful suggestions and critical reading of the manuscript.

Author contributions

J.A. designed the research, performed the experiments, managed and analyzed samples and datasets, interpreted results, wrote and revised the manuscript. A.M. conceived and designed the research, interpreted results of experiments, and edited and revised the manuscript. M.T.S. analyzed samples. D.L., E.T., and J.M. managed and analyzed datasets. All authors read and approved the final manuscript.

Funding

Funding was provided by Consejo Nacional de Ciencia y Tecnología, México (Grant No. 549678), Ministerio de Ciencia e Innovación (Grant No. SAF201459945-R), Red de Investigación Renal REDinREN (Grant No. 12/0021/0013) and Quality Mention from the Generalitat de Catalunya (Grant No. 2017 SGR).

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to A.M.
Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021